Filing Details
- Accession Number:
- 0000891293-15-000009
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-03-06 17:12:50
- Reporting Period:
- 2015-03-04
- Filing Date:
- 2015-03-06
- Accepted Time:
- 2015-03-06 17:12:50
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
891293 | Cti Biopharma Corp | CTIC | Pharmaceutical Preparations (2834) | 911533912 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1557551 | Matthew Plunkett | 3101 Western Avenue, Suite 600 Seattle WA 98121 | Evp, Corporate Development | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2015-03-04 | 1,200 | $2.39 | 858,023 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-03-04 | 1,100 | $2.40 | 856,923 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-03-04 | 1,800 | $2.40 | 855,123 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-03-04 | 1,000 | $2.41 | 854,123 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-03-04 | 1,700 | $2.41 | 852,423 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-03-04 | 300 | $2.42 | 852,123 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-03-04 | 2,800 | $2.42 | 849,323 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-03-04 | 200 | $2.43 | 849,123 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-03-04 | 600 | $2.43 | 848,523 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-03-04 | 200 | $2.44 | 848,323 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-03-04 | 1,100 | $2.44 | 847,223 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The sale was effected pursuant to a Rule 10b5-1 trading plan.